Case Studies in T2DM A Comprehensive Management Approach

Size: px
Start display at page:

Download "Case Studies in T2DM A Comprehensive Management Approach"

Transcription

1 Case Studies in T2DM A Comprehensive Management Approach John E. Anderson, MD The Frist Clinic Nashville, TN 43 yo Latina woman with 5 yrs T2DM. Originally diagnosed with PCOS and IGT by GYN at 32 yo. Begun on Metformin XR titrated to 2000 mg daily by GYN and subsequently T2DM. Completed comprehensive diabetes self management education at diagnosis, with A1C decreasing from 7.5 to 6.7%. Has had 2 outpatient walk in clinic visits for acute illnesses in the past year and GYN followup, but no visits to her primary care physician in 2 years. A1C at GYN visit 8.5% and referral back for diabetes care. Comorbidities: PCOS Hypertension Dyslipidemia Obesity Social History: Psychology professor at liberal arts college Lives with long term boyfriend No children, family nearby town Family History: both parents alive, mother with T2DM brother: recent hospitalization with angina, hx pre DM 1

2 Medications: Metformin XR Simvastatin Lisinopril/HCTZ 2000 mg/dl 20 mg daily 20 mg daily Physical Examination: Wt: 186 lb Ht: 63 BMI: 32.9 Normal Exam Laboratory Evaluation (within 30 days) gluc: 161 (fasting) A1C: 8.5% BP: 148/82 mmhg lipids: chol 199 HDL C 46 ms/dl LDL C 121 mg/dl egfr: > 90 She presents concerned about her overall health and wants to discuss ways to improve her health. States her brother s recent admission was a wake up call. Using the Comprehensive Assessment Tool, let s interview Alpina 2

3 Goals: CVD/CKD: A1C / blood glucose target and monitoring? BP goal New members of the care team? DSME? CV Assessment? CKD? Therapeutic Treatment Plan: Lifestyle Management? Pharmacologic Therapy? Referrals? Monitoring? Follow up? 60 yo White man with 8 year history of T2DM. A1C 7.6% at diagnosis prescribed lifestyle management with A1C achieved < 7%. Over the next 6 years A1Cs have ranged between 7.7% to 8.4% as medications have been added. Completed DSME after initial diagnosis. States to adherence with his medical regimen but is getting confused and light headed several times over the past month and 3 times last week. Monitors glucoses sporadically and occasional episodes of hypoglycemia (<70 mg/dl) noted. He treats the episodes with sugary drinks or candy. Comorbidities: Hypertension Obesity CKD PCI 2 years prior Hospitalized one week prior for CHF Social History: Retail clerk for an auto parts store Divorced father of two (adult children), lives alone Family History: father: deceased age 74 yo, T2DM, CVD, MI mother: living aged 82 yo, T2DM, HTN brother: living aged 58 yo, HTN sister: living aged 56 yo, T2DM, HTN 3

4 Medications: Metformin XR Sitagliptin Insulin glargine u 100 Atorvastatin Losartan/HCTZ ASA 2000 mg daily 100 mg daily 65 units daily 40 mg daily 100/25 mg daily 81 mg daily Physical Examination: Wt: 263 lbs Ht: 70 BMI: 37.7 BP: 144/82 EXTR: 1+ pedal edema bilaterally Laboratory Evaluation: gluc: 114 mg/dl (fasting) A1C: 8.3% lipids (fasting): chol 199 mg/dl HDL C 38 egfr: 57 ml/mm/1.73 m 2 LDL C 116 mg/dl He presents for follow up after hospitalization Using the Comprehensive Assessment Tool, let s interview Pete 4

5 Goals: CVD/CKD: A1C / blood glucose target and monitoring? BP goal New members of the care team? DSME? CV Assessment? CKD? Therapeutic Treatment Plan: Lifestyle Management? Pharmacologic Therapy? Referrals? Monitoring? Follow up? 77 yo black man with a 17 year hx of T2DM. Has progressed through multiple oral agents and is now on basal insulin but with poor glycemic control. He still drives but occasionally misses his follow up visits since he lives 30 miles from the office. Comorbidities: Advancing Parkinson s Disease Hypertension Dyslipidemia Obesity Major Depression ASCVD with hx CABG 10 years prior OA knees Social History: Widower in the past year, lives alone Retired machinist 3 adult children 2 daughters, 1 son Family History: both parents deceased brother: age 83 yo in a SNF 5

6 Medications: Metformin Empagliflozin Pioglitazone Sitagliptin Insulin glargine u 100 Metoprolol Lisinopril Spironolactone Rosuvastatin Levodopa/Carbidopa Ropinirole Wellbutrin XL Sertraline Trazodone ASA 1000 mg BID 25 mg BID 15 mg daily 100 mg daily 55 units daily 50 mg BID 40 mg daily 25 mg daily 20 mg daily 25/100 mg TID 2 mg QHS 300 mg daily 100 mg daily 50 mg QHS 81 mg daily Physical Examination: Wt: 223 lbs Ht: 69 BMI: BP: 132/76 Neuro: pill rolling tremor upper extremities shuffling gait Laboratory Evaluation: gluc (fasting): 187 A1C: 9.4% lipids: chol 187 mg/dl HDL C 34 LDL C 62 mg/dl TRIG: 370 mg/d egfr: 67 ml/mm/1.73 m 2 He presents today for a 3 month follow up of his T2DM. 6

7 Using the Comprehensive Assessment Tool, let s interview Pete Goals: CVD/CKD: A1C / blood glucose target and monitoring? BP goal New members of the care team? DSME? CV Assessment? CKD? Therapeutic Treatment Plan: Lifestyle Management? Pharmacologic Therapy? Referrals? Monitoring? Follow up? 7

Complete this CE activity online at ProCE.com/InsulinPart2

Complete this CE activity online at ProCE.com/InsulinPart2 Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over

More information

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity

More information

American Diabetes Association 2018 Guidelines Important Notable Points

American Diabetes Association 2018 Guidelines Important Notable Points American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Diabetes Mellitus: Implications of New Clinical Trials and New Medications Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October

More information

A Practical Approach to the Use of Diabetes Medications

A Practical Approach to the Use of Diabetes Medications A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE

More information

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide

More information

Vipul Lakhani, MD Oregon Medical Group Endocrinology

Vipul Lakhani, MD Oregon Medical Group Endocrinology Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment

More information

OBESITY IN TYPE 2 DIABETES

OBESITY IN TYPE 2 DIABETES OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents

More information

CURRENT CONTROVERSIES IN DIABETES CARE

CURRENT CONTROVERSIES IN DIABETES CARE CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact

More information

ABFM Diabetes SAM Part 4

ABFM Diabetes SAM Part 4 ABFM Diabetes SAM Part 4 37. A 55-year-old male with type 2 diabetes mellitus has a chronic history of reduced libido and erectile dysfunction. On examination you note hepatomegaly and mild testicular

More information

Learning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications

Learning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications Treatment Strategies to Maximize the Value of Diabetes Medications Presenters: Jennifer Toy, PharmD, BCACP and Crystal Zhou, PharmD, APh AHSCP, BCACP Learning Objectives 1. Discuss which patients may benefit

More information

Case 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized?

Case 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized? Case 1 A primary care colleague inquires what to do with a patient (HFrEF in NSR) who has a digoxin level of 2.8ng/ml. Level was obtained at 10am, patient takes all medications at one time upon arising

More information

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013 CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI

More information

Reason for referral: provide patient education on management of hypoglycemia and glucose monitor

Reason for referral: provide patient education on management of hypoglycemia and glucose monitor Meet Robin Sawyer (otherwise known as PT 1): Let s Create a Care Plan! Reason for referral: provide patient education on management of hypoglycemia and glucose monitor History of present illness: 40 45

More information

Updates in Cardiovascular Recommendations for Diabetic Patients

Updates in Cardiovascular Recommendations for Diabetic Patients Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

VS: BP 165/90, P 98, RR 18, T 37 C; waist circ 38 in, Wt 240 lbs (109 kg), Ht 5'8''

VS: BP 165/90, P 98, RR 18, T 37 C; waist circ 38 in, Wt 240 lbs (109 kg), Ht 5'8'' IMC Didactic Case-Diabetes Mellitus Chief Complaint "I was recently diagnosed with diabetes and would like to have my blood sugar tested. I think that my blood sugar is running low because I have the shakes

More information

Evaluating the Cardiovascular Benefits of Antidiabetic Medications

Evaluating the Cardiovascular Benefits of Antidiabetic Medications Evaluating the Cardiovascular Benefits of Antidiabetic Medications Target Audience: Pharmacists ACPE#: 0202-0000-18-054-L01-P Activity Type: Application-based Disclosures Stuart T. Haines has no relevant

More information

Management of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test

Management of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening

More information

Individualizing Care for Patients with Type 2 Diabetes

Individualizing Care for Patients with Type 2 Diabetes Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches

More information

Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk

Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,

More information

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Management of Diabetes Mellitus: A Primary Care Perspective

Management of Diabetes Mellitus: A Primary Care Perspective Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening

More information

Advanced Pharmacology Diabetes Homework

Advanced Pharmacology Diabetes Homework Advanced Pharmacology Diabetes Homework Points: 25 Comments: Name: Tracy Hill WU ID #: 20015608 E-mail: tracy.hill@washburn.edu _TH I hereby certify that the work submitted is my own, and that I have not

More information

Reducing ASCVD Risk Focus on Lipids. Carol Marsh, DNP, APRN, CNP, FPCNA Clinical Lipid Specialist

Reducing ASCVD Risk Focus on Lipids. Carol Marsh, DNP, APRN, CNP, FPCNA Clinical Lipid Specialist Reducing ASCVD Risk Focus on Lipids Carol Marsh, DNP, APRN, CNP, FPCNA Clinical Lipid Specialist By age 2, many children have one or more risk factors for heart disease. At 40 years old, the lifetime risk

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture.

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. 1 Phar6122: CV section Date: 3/10/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In

More information

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College

More information

American Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications

American Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications American Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications Juan Pablo Frias, M.D., FACE President and CEO, National Research Institute, Los Angeles, CA Clinical Faculty,

More information

Cardiovascular disease and diabetes Vascular harmony

Cardiovascular disease and diabetes Vascular harmony Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics

More information

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now? Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl

More information

Adult Diabetes Clinician Guide NOVEMBER 2017

Adult Diabetes Clinician Guide NOVEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space? Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Management of Diabetes

Management of Diabetes Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships

More information

Type 2 Diabetes Mellitus Insulin Therapy 2012

Type 2 Diabetes Mellitus Insulin Therapy 2012 Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration

More information

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Clinical Cases in Diabetes Management. Joseph Cook D.O. Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

Pharmacology Challenges: Managing Statin Myalgia

Pharmacology Challenges: Managing Statin Myalgia Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80

More information

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

Type 2 Diabetes Performance Improvement Initiative: Chart Reviews. Lara Zisblatt Boston University School of Medicine Boston, MA

Type 2 Diabetes Performance Improvement Initiative: Chart Reviews. Lara Zisblatt Boston University School of Medicine Boston, MA Type 2 Diabetes Performance Improvement Initiative: Chart Reviews Lara Zisblatt Boston University School of Medicine Boston, MA Participants in the Program 487 people registered 217 people started the

More information

Participants in the Program

Participants in the Program Type 2 Diabetes Performance Improvement Initiative: Chart Reviews Lara Zisblatt Boston University School of Medicine Boston, MA Participants in the Program 487 people registered 217 people started the

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with

More information

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the

More information

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Long-Term Complications of Diabetes Mellitus Macrovascular Complication Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

11/4/2014. Outline. Pharmacists Objectives. Diabetes Update: What s New in Pharmacy Technician Objectives. Overview: Type 2 Diabetes Mellitus

11/4/2014. Outline. Pharmacists Objectives. Diabetes Update: What s New in Pharmacy Technician Objectives. Overview: Type 2 Diabetes Mellitus Diabetes Update: What s New in 2014 Dr. Amy P. Witte, Pharm.D. Associate Professor, Pharmacy Practice UIW Feik School of Pharmacy CTSHP Fall Seminar La Cantera Hill Country Resort October 25, 2014 Pharmacists

More information

Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?

Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM

More information

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine

More information

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator

More information

Interprofessional Outpatient Clinic Polypharmacy Management. Objectives

Interprofessional Outpatient Clinic Polypharmacy Management. Objectives Interprofessional Outpatient Clinic Polypharmacy Management Brett Hoffecker, MD University of Kansas School of Medicine Wichita Family Medicine Residency Program at Via Christi April 10th, 2015 Objectives

More information

Metabolic Syndrome in Asians

Metabolic Syndrome in Asians Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly

More information

Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management

Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care

More information

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture.

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. 1 Phar6122: CV section Date: 3/21/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In

More information

Women and Vascular Disease

Women and Vascular Disease Women and Vascular Disease KEVIN F. REBECK PA-C VASCULAR TRANSPLANT SURGERY 1 The Scope of the Problem One woman dies every minute from cardiovascular disease in the U.S.! The Scope of the Problem CVD

More information

CURRENT ISSUES IN DIABETES MANAGEMENT

CURRENT ISSUES IN DIABETES MANAGEMENT CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2011 BMI

More information

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call, , mail).

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call,  , mail). Blood Pressure Management and Control Protocol BP Management: A) BP goal: Achieve blood pressure values less than 130/80mmHg. B) Process: Have participants measure their blood pressure daily at a standard

More information

Diabetes Complications Guideline Based Screening, Management, and Referral

Diabetes Complications Guideline Based Screening, Management, and Referral Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes

More information

4 th and Goal To Go How Low Should We Go? :

4 th and Goal To Go How Low Should We Go? : 4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose

More information

American Academy of Insurance Medicine

American Academy of Insurance Medicine American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker

More information

Patient is a 60 YO MALE seen in clinic for diabetes management follow-up. Allergies/ADEs: FLUNISOLIDE, PRIMIDONE, ALEVE CAPLET, CARBAMAZEPINE

Patient is a 60 YO MALE seen in clinic for diabetes management follow-up. Allergies/ADEs: FLUNISOLIDE, PRIMIDONE, ALEVE CAPLET, CARBAMAZEPINE Patient is a 60 YO MALE seen in clinic for diabetes management follow-up. Allergies/ADEs: FLUNISOLIDE, PRIMIDONE, ALEVE CAPLET, CARBAMAZEPINE Dx/Hx: uncontrolled DM and HTN Lifestyle: Patient usually sleeps

More information

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk Psychotropic Medications & Cardiometabolic Risk Sam Ellis, PharmD, BCPS, CDE Associate Professor University of Colorado School of Pharmacy Introduction Second GenerationAntipsychotics (SGA) first FDA approved

More information

Application of the Diabetes Algorithm to a Patient

Application of the Diabetes Algorithm to a Patient Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent

More information

Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice

Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for

More information

How to Use the ADA Type 2 Diabetes Treatment Algorithm. Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP

How to Use the ADA Type 2 Diabetes Treatment Algorithm. Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP How to Use the ADA Type 2 Diabetes Treatment Algorithm Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP 8 ACOFP 55th Annual Convention & Scientific Seminars ACOFP FULL DISCLOSURE FOR CME ACTIVITIES Please

More information

Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes!

Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen

More information

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016 What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with

More information

A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies

A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention

More information

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca

More information

Learning Objectives. Patient Case

Learning Objectives. Patient Case Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations

More information

Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Titration Algorithm

Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Titration Algorithm Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Algorithm Updated 9/13/2017 PHASE Populations DM: type 2 ASCVD: hx heart attack/cad, CVA, TIA, AAA, Sx PAD Lifestyle Modifications

More information

Prediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest.

Prediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest. Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen

More information

Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes

Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks

Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES

More information

Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events

Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events How does all this play out when it comes to treating patients with type 2 DM who have chronic kidney disease? Therapeutic

More information

Prevention of Cardiovascular Disease

Prevention of Cardiovascular Disease Save Thais from Heart Diseases 2019 Prevention of Cardiovascular Disease Orawan Anupraiwan, MD. Central Chest Institute of Thailand ASCVD Prevention Pyramid Risk categories Very high-risk High-risk Documented

More information

Diabetes Update: Diabetes Management In Primary Care. Jonathon M. Firnhaber, MD, FAAFP

Diabetes Update: Diabetes Management In Primary Care. Jonathon M. Firnhaber, MD, FAAFP Diabetes Update: Diabetes Management In Primary Care Jonathon M. Firnhaber, MD, FAAFP Learning objectives 1. Critically evaluate the evidence emerging within diabetes research as it applies to recommendations

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships

More information

Diabetes Risk Assessment and Treatment

Diabetes Risk Assessment and Treatment Diabetes Risk Assessment and Treatment Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University Baltimore, Maryland, USA

More information

Know Your Diabetes by Heart: Diabetes and Cardiovascular Disease. Eric L. Johnson, MD February 19, 2019

Know Your Diabetes by Heart: Diabetes and Cardiovascular Disease. Eric L. Johnson, MD February 19, 2019 Know Your Diabetes by Heart: Diabetes and Cardiovascular Disease Eric L. Johnson, MD February 19, 2019 WELCOME AND REMINDERS Use chat for questions and comments Slides and recording will be available on

More information

Disclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2

Disclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical

More information

Section 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for

Section 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for Section 1: 1: Trends 1 Patients in the Diabetes Register 2 Gender of Patients with Diabetes 2 Age of Patients with Diabetes 3 Diabetes Type 3 Duration of Diabetes 4 Weight Control 5 Hemoglobin A1c 6 Blood

More information

Wayne Gravois, MD August 6, 2017

Wayne Gravois, MD August 6, 2017 Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion

More information

Diabetes Treatment Update

Diabetes Treatment Update Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers

More information

STANDARDS OF MEDICAL CARE IN DIABETES 2014

STANDARDS OF MEDICAL CARE IN DIABETES 2014 STANDARDS OF MEDICAL CARE IN DIABETES 2014 I. CLASSIFICATION AND DIAGNOSIS Classification of Diabetes Type 1 diabetes β-cell destruction Type 2 diabetes Progressive insulin secretory defect Other specific

More information

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Finding the sweet spot: Individualized targets for older adults with Type 2 DM

Finding the sweet spot: Individualized targets for older adults with Type 2 DM Finding the sweet spot: Individualized targets for older adults with Type 2 DM Samuel C. Durso, M.D., M.B.A. Mason F. Lord Professor of Medicine Director, Division of Geriatric Medicine and Gerontology

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for

More information

A 45 year old African American man presents to the IMC with a chief complaint of my

A 45 year old African American man presents to the IMC with a chief complaint of my AN EVIDENCE BASED APPROACH TO HYPERTENSION AND HYPERLIPIDENIA: A CASE STUDY A 45 year old African American man presents to the IMC with a chief complaint of my pressure is high. Apparently he recently

More information

New Drugs for Diabetes

New Drugs for Diabetes NEW DRUGS FOR DIABETES Which Ones, For Which Patients? Disclosure Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu No relevant financial relationships

More information